Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16)

被引:57
作者
Chen, Li-Sheng [1 ]
Liao, Chao-Sheng [2 ]
Chang, Shu-Hui [1 ]
Lai, Hsin-Chih [3 ]
Chen, Tony Hsiu-Hsi [1 ]
机构
[1] Natl Taiwan Univ, Coll Publ Hlth, Ctr Biostat Consultant,Inst Prevent Med, Grad Inst Epidemiol,Div Biostat, Taipei 10764, Taiwan
[2] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei, Taiwan
[3] Natl Taiwan Univ, Dept Clin Lab Sci & Med Biotechnol, Taipei 10764, Taiwan
关键词
D O I
10.1258/096914107782912022
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives We aimed to determine the optimal cut-off of the immunochemical faecal occult blood test (iFOBT) by using cost-effectiveness analysis. Methods A total of 22,672 subjects aged 50 years or older were invited to have an uptake of iFOBT. We collected data from screen-detected cases for the cut-off above 100 ng/mL and obtained interval cancers from a nationwide cancer registry for a cut-off below 100ng/mL. We found a total of 65 colorectal cancer (CRC) cases, including 43 detected by screen and 22 diagnosed between screens (interval cases). The optimal cut-off was first determined by receiver operating characteristics (ROC) curve analysis. Formal economic evaluation was further applied to identifying the optimal cut-off by assessing the minimum incremental cost-effectiveness ratio (ICER), an indicator for cost per life year gained (effectiveness), given a series of cut-offs of iFOBT, ranging from 30 to 200 ng/mL compared with no screening. Results ROC curve analysis found the optimal cut-off of iFOBT to be 100ng/mL at which the sensitivity, false-positive and odds of being affected given a positive result were 81.5% (70.2%-89.2%), 5.7% (5.4%-6.0%) and 1.24 (1.19-1.32), respectively. The area under ROC curve was 0.87 (0.81-0.93). In economic appraisal, the screening programme irrespective of any cut-off dominated (less cost and more effectiveness) over the control group. The optimal cut-off (the lowest ICER) was 110 ng/mL at which an average of 0.054 life year was gained and that of 950 ($US) was saved. Conclusions We used cost-effectiveness to identify 110 ng/mL as the optimal cut-off of iFOBT in a Taiwanese population-based screening for CRC. Our model provides a useful approach for health policy-makers in designing population-based screening for CRC to determine the optimal cut-off of iFOBT when cost and effectiveness need to be taken into account.
引用
收藏
页码:191 / 199
页数:9
相关论文
共 15 条
[1]   ACCURACY OF FECAL OCCULT BLOOD SCREENING FOR COLORECTAL NEOPLASIA - A PROSPECTIVE-STUDY USING HEMOCCULT AND HEMOQUANT TESTS [J].
AHLQUIST, DA ;
WIEAND, HS ;
MOERTEL, CG ;
MCGILL, DB ;
LOPRINZI, CL ;
OCONNELL, MJ ;
MAILLIARD, JA ;
GERSTNER, JB ;
PANDYA, K ;
ELLEFSON, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (10) :1262-1267
[2]   A comparison of fecal occult-blood tests for colorectal-cancer screening [J].
Allison, JE ;
Tekawa, IS ;
Ransom, LJ ;
Adrain, AL .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :155-159
[3]   Community-based multiple screening model - Design, implementation, and analysis of 42,387 participants Taiwan community-based integrated screening group [J].
Chen, THH ;
Chiu, YH ;
Luh, DL ;
Yen, MF ;
Wu, HM ;
Chen, LS ;
Tung, TH ;
Huang, CC ;
Chan, CC ;
Shiu, MN ;
Yeh, YP ;
Liou, HH ;
Liao, CS ;
Lai, HC ;
Chiang, CP ;
Peng, HL ;
Tseng, CD ;
Yen, MS ;
Hsu, WC ;
Chen, CH .
CANCER, 2004, 100 (08) :1734-1743
[4]   A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer [J].
Cole, SR ;
Young, GP ;
Esterman, A ;
Cadd, B ;
Morcom, J .
JOURNAL OF MEDICAL SCREENING, 2003, 10 (03) :117-122
[5]  
Greenberg PD, 2000, AM J GASTROENTEROL, V95, P1331
[6]   Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [J].
Hardcastle, JD ;
Chamberlain, JO ;
Robinson, MHE ;
Moss, SM ;
Amar, SS ;
Balfour, TW ;
James, PD ;
Mangham, CM .
LANCET, 1996, 348 (9040) :1472-1477
[7]   Randomised study of screening for colorectal cancer with faecal-occult-blood test [J].
Kronborg, O ;
Fenger, C ;
Olsen, J ;
Jorgensen, OD ;
Sondergaard, O .
LANCET, 1996, 348 (9040) :1467-1471
[8]   REDUCING MORTALITY FROM COLORECTAL-CANCER BY SCREENING FOR FECAL OCCULT BLOOD [J].
MANDEL, JS ;
BOND, JH ;
CHURCH, TR ;
SNOVER, DC ;
BRADLEY, GM ;
SCHUMAN, LM ;
EDERER, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (19) :1365-1371
[9]   Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer [J].
Nakama, H ;
Zhang, B ;
Zhang, X .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (03) :398-401
[10]  
Saito H, 1996, Nihon Rinsho, V54, P1421